Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer

Trial Profile

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Cetuximab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2019 Results (n=18) evaluating the plasma-derived exosomes as bio-markers of response to immunotherapy in patients with head and neck squamous cell carcinoma patients presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed,according to the results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top